Top

Published in:

Open Access 07-12-2022 | Pancreatoduodenostomy | Review Article

How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

Authors: Masayuki Imamura, Izumi Komoto, Yoshiro Taki

Published in: Surgery Today | Issue 12/2023

Abstract

In patients with multiple endocrine neoplasia type 1 syndrome (MEN 1) and Zollinger–Ellison syndrome (ZES), gastrinomas arise from the duodenum, about 60% are multiple, and about 15% of patients have coexisting pancreatic gastrinomas, which can be localized by the selective arterial secretagogue injection test (SASI test). The guidelines (GLs) by the Japanese Neuroendocrine Tumor Society (JNETS) recommend surgical resection for functioning duodenopancreatic neuroendocrine tumors (NETs), including gastrinomas, in patients with MEN1 (Grade A, 100% agreement among members). Conversely, the GLs of the National Comprehensive Cancer Network (NCCN) in the USA recommend observation and treatment with proton pump inhibitors (PPIs) or exploratory surgery for occult gastrinomas. An international Consensus Statement (ICS) from the European Union (EU) also does not recommend resection of gastrinomas in patients with MEN1, despite some surgeons having reported surgery being curative for gastrinomas in MEN1 patients. In this review, we discuss the serious side effects and tumorigenic effects of the prolonged use of PPIs and the safety and curability of surgery, supported by our results of curative surgery for gastrinomas in 20 patients with MEN1 over 30 years. We conclude that surgery should be the first-line treatment for gastrinomas in MEN1 patients.

Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol. 2011;17(10):1343–53. https://doi.org/10.3748/wjg.v17.i10.1343.CrossRefPubMedPubMedCentral

Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322:723–7.CrossRefPubMed

Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006;12:5440–6.CrossRefPubMedPubMedCentral

Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg. 1989;210(6):710–8. https://doi.org/10.1097/00000658-198912000-00004.CrossRefPubMedPubMedCentral

Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the 40 patients with Zollinger-Ellison syndrome, hypoglycemia or both. J Intern Med. 1998;243:495–500.CrossRefPubMed

Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, et al. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol. 2021;56(11):1033–44. https://doi.org/10.1007/s00535-021-01827-7 (Published online 2021 Sep 29).CrossRefPubMedPubMedCentral

Shah MH, Goldner WS, Al B, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68. https://doi.org/10.6004/jnccn.2021.0032.CrossRefPubMed

Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the men1 syndrome—an international consensus statement. Neuroendocrinology. 2021;111(7):609–30. https://doi.org/10.1159/000511791 (Epub 2020 Sep).CrossRefPubMed

Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg. 2013;257(2):308–14. https://doi.org/10.1097/SLA.0b013e3182536339.CrossRefPubMed

10.

Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg. 2007;94(11):1331–41. https://doi.org/10.1002/bjs.5987.CrossRefPubMed

11.

Kong W, Albers MB, Manoharan J, Goebel JN, Kann PH, Jesinghaus M, et al. Pancreaticoduodenectomy is the best surgical procedure for Zollinger-Ellison syndrome associated with multiple endocrine neoplasia type 1. Cancers (Basel). 2022;14(8):1928. https://doi.org/10.3390/cancers14081928.CrossRefPubMed

12.

Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu-Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGRS) definition and grading of postoperative pancreatic fistula:11years after. Surgery. 2017;161(3):584–91.CrossRefPubMed

13.

Kato M, Imamura M, Hosotani R, Shimada Y, Doi R, Itami A, et al. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg. 2000;24:1425–30.CrossRefPubMed

14.

Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320–8. https://doi.org/10.1097/00000658-199409000-00008 (Discussion 328-30 PMID: 7916560).CrossRefPubMedPubMedCentral

15.

Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9. https://doi.org/10.1097/01.sla.0000234802.44320.a5 (PMID: 16926567).CrossRefPubMedPubMedCentral

16.

Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242(6):757–64. https://doi.org/10.1097/01.sla.0000189549.51913.d8 (PMID: 16327485).CrossRefPubMedPubMedCentral

17.

Zollinger RM, Ellison EH. Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–28.CrossRefPubMedPubMedCentral

18.

Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA. 1994;271(18):1429–35. https://doi.org/10.1001/jama.271.18.1429.CrossRefPubMed

19.

Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51(3):177–94. https://doi.org/10.1007/s00535-016-1166-4 (Epub 2016 Feb 15).CrossRefPubMed

20.

Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1):e12759. https://doi.org/10.7759/cureus.12759.CrossRefPubMedPubMedCentral

21.

Perrier M, Delemer B, Deguelte S, Legros V, Brixi H, Kianmanesh R, et al. Total gastrectomy for severe PPI-induced hypomagnesemia in a MEN1/ZES patient. Pancreatology. 2021;21(1):236–9. https://doi.org/10.1016/j.pan.2020.12.002 (Epub 2020 Dec 7).CrossRefPubMed

22.

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6. https://doi.org/10.1056/NEJMc066308 (PMID: 17065651).CrossRefPubMed

23.

Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci. 2019;20(20):5203. https://doi.org/10.3390/ijms20205203.CrossRefPubMedPubMedCentral

24.

Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013;47(6):773–80. https://doi.org/10.1345/aph.1R556 (Epub 2013 Apr 30).CrossRefPubMed

25.

Food and Drug Administration. FDA Drug Safety Communication: low magnesium levels can be associated with long‑term use of proton pump inhibitors drugs. https://www.fda.gov/drugs/drug‑safety‑and‑availability/fda‑drug‑safety‑communication‑low‑magnesium‑levels‑can‑be‑associated‑long‑term‑use‑proton‑pump. Accessed 29 Mar, 2021

26.

Food and Drug Administration. FDA Drug Safety Communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. https://www.fda.gov/drugs/postmarket‑drug‑safety‑information‑patients‑and‑providers/fda‑drug‑safety‑communication‑possible‑increased‑risk‑fractures‑hip‑wrist‑and‑spine‑use‑proton‑pump. Accessed 29 Mar, 2021

27.

Ness-Jensen E, Bringeland EA, Mattsson F, Mjønes P, Lagergren J, Grønbech JE, et al. Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: a prospective population-based nested case-control study. Int J Cancer. 2021;148(8):1879–86. https://doi.org/10.1002/ijc.33354 (Epub 2020 Nov).CrossRefPubMed

28.

Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-type1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136:1267–74.CrossRefPubMed

29.

Anjiki H, Mukaisho KI, Kadomoto Y, Doi H, Yoshikawa K, Nakayama T, et al. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy. Clin J Gastroenterol. 2017;10(2):128–36. https://doi.org/10.1007/s12328-017-0714-7 (Epub 2017 Feb 3).CrossRefPubMed

30.

Fossmark R, Calvete O, Mjones P, Benitez J, Waldum HL. ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPASE alpha subunit. APMIS. 2016;124:561–6 (CrossRef PubMed).CrossRefPubMed

31.

Bakke I, Qvigstad G, Brenna E, Sandvik A, Waldum HL. Gastrin has a specific proliferative effect on the rat enetrochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand. 2000;169:29–37 (CrossRef).CrossRefPubMed

32.

Nakajima T, Konda Y, Izumi Y, Kanai M, Hayashi N, Chiba T, et al. Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors. Am J Physiol Gastrointest Liver Physiol. 2002;282:G359–66.CrossRefPubMed

33.

Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas P. Systematic Review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42:649–63 (CrossRef).CrossRefPubMed

34.

Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987;205:230–9.CrossRefPubMedPubMedCentral

35.

Ingemansson S, Larsson LI, Lunderquist A, Stadil F. Pancreatic vein catheterization with gastrin assay in normal patients and in patients with the Zollinger-Ellison syndrome. Am J Surg. 1977;134:558–63.CrossRefPubMed

36.

Zollinger RM. Treatment of gastrinoma. Mount Sinai J Med. 1984;51:401–3.

37.

Vogel SB, Wolfe MM, McGuigan JE, Hawkins IF Jr, Howard RJ, Woodward ER. Localization and resection of gastrinomas in Zollinger-Ellison syndrome. Ann Surg. 1986;205:550–6.CrossRef

38.

Norton JA, Sugarbaker PH, Doppman JL, Wesley RA, Maton PN, Gardner JD, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:352–9. https://doi.org/10.1097/00000658-198604000-00003.CrossRefPubMedPubMedCentral

39.

Doppman JL, Miller DL, Chang R, Maton PN, London JF, Gardner JD, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174:25–9. https://doi.org/10.1148/radiology.174.1.2294556.CrossRefPubMed

40.

Turner JJ, Wren AM, Jackson JE, Thakker RV, Meeran K. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf). 2002;57:821–5.CrossRefPubMed

41.

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601. https://doi.org/10.1007/s00259-017-3728-y (Epub 2017 May 25).CrossRefPubMed

42.

Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg. 2005;29:203–7.CrossRefPubMed

43.

Chung RS, Church JM, Van Stolk R. Pancreas-sparing duodenectomy: indications, surgical technique and results. Surgery. 1995;117:254–9.CrossRefPubMed

44.

Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011.CrossRefPubMed

45.

Cantalejo-Díaz M, Ramia-Ángel JM, Palomares-Cano A, Serradilla-Martín M. Pancreas-preserving total duodenectomy: a systematic review. Dig Surg. 2021;38:186–97. https://doi.org/10.1159/000515718 (Epub 2021 May 17).CrossRefPubMed

Title: How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?
Authors: Masayuki Imamura
Izumi Komoto
Yoshiro Taki
Publication date: 07-12-2022
Publisher: Springer Nature Singapore
Keywords: Pancreatoduodenostomy
Pancreatoduodenostomy
Proton Pump Inhibitors
Published in: Surgery Today / Issue 12/2023
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-022-02627-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2023

Single-incision transgastric resection for gastric gastrointestinal stromal tumors in anatomically challenging locations

Anastomotic time was associated with postoperative complications: a cumulative sum analysis of thoracoscopic repair of tracheoesophageal fistula in a single surgeon’s experience

Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience

Gastrectomy reduces pancreatic secretory function via pancreatic atrophy

Efficacy of left colic artery preservation with D3 lymph node dissection in laparoscopic surgery for advanced sigmoid and rectal cancer

Using machine learning models to predict the surgical risk of children with pancreaticobiliary maljunction and biliary dilatation